| | |
| Clinical data | |
|---|---|
| Other names | NBOMe; NBOMe-PEA; N-(2-Methoxybenzyl)phenethylamine |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C16H19NO |
| Molar mass | 241.334 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
PEA-NBOMe, also known as N-(2-methoxybenzyl)phenethylamine, is a drug of the phenethylamine and N-benzylphenethylamine (NB; NBOMe) families related to phenethylamine (PEA). [1] [2] It is the N-(2-methoxybenzyl) derivative of phenethylamine. [1] [2] The drug is a parent compound of the NBOMe family of psychedelic drugs, such as 25I-NBOMe. [1] [2] [3] No data on the pharmacology or toxicity of PEA-NBOMe are available. [1] [2] In any case, based on structure–activity relationships, PEA-NBOMe might produce stimulant and/or hallucinogenic effects. [1] [2] The drug was encountered as a novel designer drug online in 2024. [1] [2]
Substances based on the N-(2-methoxybenzyl)phenethylamine template ('NBOMe' derivatives) play an important role in medicinal research but some of these derivatives have also appeared as 'research chemicals' for recreational use which has attracted attention worldwide.